FDA Approves Dapagliflozin Tablets (dapagliflozin) for Heart Failure Risk Reduction and Glycemic Control in Type 2 Diabetes
FDA approves a diabetes drug that also helps protect the heart in certain adults.
The FDA has approved dapagliflozin tablets to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes and establ…
A new diabetes tablet now helps control blood sugar while also lowering the risk of heart failure hospitalization for adults with heart dise…
FDA Approves Dapagliflozin Tablets (dapagliflozin) for Type 2 Diabetes and Heart Failure Risk Reduction
FDA approves a new pill for type 2 diabetes that also helps protect the heart.
The FDA has approved dapagliflozin tablets for two indications in adults with type 2 diabetes mellitus: to improve glycemic control and to r…
A new FDA-approved pill for type 2 diabetes now helps lower blood sugar while also reducing the risk of hospitalization for heart failure.
Meta-analysis finds SGLT2 inhibitors reduce mortality and hospitalization in older heart failure patients
Older Adults With Heart Failure May Gain Years From This Pill
A systematic review and meta-analysis of 20,844 patients aged 65+ with heart failure found SGLT2 inhibitors were associated with reduced all…
A pooled look at 10 studies in over 20,000 older adults shows SGLT2 inhibitors cut the risk of dying from any cause by about a fifth — and t…
Left bundle-branch pacing reduced death or heart failure hospitalization compared with biventricular pacing in heart failure with left bundle-branch block.
Left bundle-branch pacing reduced death or hospitalization compared to biventricular pacing in heart failure patients
This randomized clinical trial enrolled 200 patients at six centers in China with heart failure, left bundle-branch block, and an LVEF of 35…
Left bundle-branch pacing cuts heart failure hospitalizations by 70% compared to standard biventricular pacing in patients with severe heart…
Conduction system pacing showed inferior outcomes compared to biventricular pacing in adults with heart failure and left bundle-branch block.
New Brazil study found conduction system pacing was inferior to biventricular pacing for heart failure patients.
This randomized clinical trial enrolled 173 adults with symptomatic heart failure with reduced ejection fraction and left bundle-branch bloc…
A new Brazil trial found conduction system pacing was worse than standard biventricular pacing for heart failure patients, increasing risks …
Elevated circulating Lp(a) levels associated with increased heart failure incidence in 400,631 participants.
Does high Lp(a) truly raise your risk of heart failure, and what does that mean for you?
This meta-analysis of prospective cohort studies involving 400,631 participants evaluated the association between circulating Lp(a) levels a…
High levels of a specific blood protein called Lp(a) are linked to a 34% higher risk of developing heart failure, with the danger rising sha…
Observational EHR study suggests GLP-1 RA may have lower risk than SGLT2i for HF outcomes
Observational study links GLP-1 RA to lower risk than SGLT2i in heart failure patients
An observational study using real-world EHR data from Stony Brook University Hospital compared GLP-1 RAs to SGLT2 inhibitors in patients wit…
In heart failure patients, GLP-1 receptor agonists showed a lower risk of death or hospitalization compared to SGLT2 inhibitors over one yea…
FDA Approves Dapagliflozin Tablets (dapagliflozin) to Reduce Heart Failure Hospitalization Risk and Improve Glycemic Control in Adults with Type 2 Diabetes
FDA approves a diabetes drug that also helps protect the heart in certain adults.
The FDA has approved dapagliflozin tablets to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus a…
A new diabetes drug is approved to lower blood sugar and cut the risk of heart failure hospitalization in adults with type 2 diabetes and he…
FDA Approves Dapagliflozin Tablets (dapagliflozin) for Heart Failure Risk Reduction and Glycemic Control in Type 2 Diabetes
FDA approves a diabetes pill that also helps protect the heart from failure.
The FDA has approved dapagliflozin tablets to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes and establ…
A new diabetes pill approved by the FDA also lowers the risk of hospitalization for heart failure in adults with type 2 diabetes.
FDA Approves Dapagliflozin Tablets (dapagliflozin) for Type 2 Diabetes and Heart Failure Risk Reduction
FDA approves a new diabetes pill that also helps protect the heart.
The FDA has approved dapagliflozin tablets for two indications: to improve glycemic control in adults with type 2 diabetes mellitus, and to …
A new daily diabetes pill now approved by the FDA helps lower blood sugar and reduces the risk of heart failure hospitalization for adults w…
FDA Approves Dapagliflozin for Reducing Heart Failure Hospitalization Risk and Improving Glycemic Control in Adults with Type 2 Diabetes
FDA approves a diabetes drug that also helps protect the heart.
The FDA has approved dapagliflozin to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and estab…
A new diabetes drug now helps lower blood sugar while also reducing the risk of heart failure hospitalization for adults with heart disease …
FDA Approves Dapagliflozin Tablets (dapagliflozin) for Heart Failure Risk Reduction and Glycemic Control in Type 2 Diabetes
FDA approves a diabetes drug that also helps lower the risk of heart failure.
The FDA has approved dapagliflozin tablets to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes and establ…
A new diabetes pill now helps lower blood sugar and reduces the risk of hospitalization for heart failure in adults with type 2 diabetes.